Hypertension Diagnostics (OTCMKTS:HDII) and TELA Bio (NASDAQ:TELA) Head-To-Head Analysis

Hypertension Diagnostics (OTCMKTS:HDIIGet Free Report) and TELA Bio (NASDAQ:TELAGet Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Institutional and Insider Ownership

94.4% of TELA Bio shares are held by institutional investors. 40.0% of Hypertension Diagnostics shares are held by company insiders. Comparatively, 5.7% of TELA Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Hypertension Diagnostics and TELA Bio, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hypertension Diagnostics 0 0 0 0 N/A
TELA Bio 0 0 3 0 3.00

TELA Bio has a consensus target price of $13.67, suggesting a potential upside of 141.03%. Given TELA Bio’s higher probable upside, analysts clearly believe TELA Bio is more favorable than Hypertension Diagnostics.

Volatility and Risk

Hypertension Diagnostics has a beta of -2.34, indicating that its stock price is 334% less volatile than the S&P 500. Comparatively, TELA Bio has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Earnings and Valuation

This table compares Hypertension Diagnostics and TELA Bio’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hypertension Diagnostics N/A N/A N/A N/A N/A
TELA Bio $58.45 million 2.39 -$46.66 million ($2.07) -2.74

Hypertension Diagnostics has higher earnings, but lower revenue than TELA Bio.

Profitability

This table compares Hypertension Diagnostics and TELA Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Hypertension Diagnostics N/A N/A N/A
TELA Bio -79.83% -201.62% -58.60%

Summary

TELA Bio beats Hypertension Diagnostics on 5 of the 9 factors compared between the two stocks.

About Hypertension Diagnostics

(Get Free Report)

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.

About TELA Bio

(Get Free Report)

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Receive News & Ratings for Hypertension Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypertension Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.